Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Radiotherapy in Combination With Pembrolizumab in Patients With PSA Persistence or Biochemical Recurrence After Radical Prostatectomy Due to Prostate Cancer

NCT04931979 is registered in ClinicalTrials.gov with Prof. Dr. med. Christian Gratzke as lead sponsor.

NCT NCT04931979
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04931979 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Radiotherapy in Combination With Pembrolizumab in Patients With PSA Persistence or Biochemical Recurrence After Radical Prostatectomy Due to Prostate Cancer
Lead sponsor
Prof. Dr. med. Christian Gratzke
Phase
Phase 2
Overall status
Unknown status
Start date
October 20, 2022
Completion date
April 1, 2026
Enrollment
49 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

biochemical recurrence of malignant neoplasm of prostate, urologic cancer